This course is also available for 1.00 AAPA Category 1 CME Credit. To access it, please scroll to the bottom of this page and select the course listed under "Related to This Activity."
Provided by American Association of Nurse Practitioners
Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck
Produced by Haymarket Medical Education (HME)
Major depressive disorder (MDD) is a disturbance of mood that may have persistent and long-term consequences impacting patients’ overall level of functioning and quality of life. Current treatment guidelines recommend an end goal of full remission; despite these recommendations, it is estimated that as few as 24% of patients with MDD receive any treatment, just 9% receive adequate treatment, and only 6% achieve full remission. In order for patients with MDD to achieve remission goals, it is imperative that they receive adequate, appropriate, and comprehensive management. Understanding the impact of residual symptoms, utilizing validated tools for monitoring treatment response, considering novel treatment approaches, and implementing strategies that support patient-provider communication and collaboration will all ultimately improve patient outcomes and support treatment goals.
This activity is intended for nurse practitioners who treat patients with MDD.
At the end of this activity, learners should be better able to:
Review the impact of residual major depressive disorder (MDD) symptoms on patient function, quality of life, and long-term outcomes
Utilize measurement-based care tactics to effectively monitor and assess symptom resolution in patients receiving therapy for MDD
Apply recommended strategies, as set forth by the American Psychiatric Association, in modifying MDD treatment to achieve long-term remission in nonresponders or partial responders to therapy
Identify patients with MDD who might benefit from new pharmacologic treatment options while considering safety and efficacy parameters
Employ the shared decision-making model (SDM) to foster communication between MDD patients and their healthcare providers
Conflict Of Interest Disclosure Policy
It is the policy of the American Association of Nurse Practitioners to require all faculty to provide disclosure of any financial relationship within the past 12 months with a commercial interest or any commercial product discussed in an educational presentation. All real or potential conflicts of interest identified must be resolved prior to program development and approval.
PROGRAM CHAIR Charles L. Raison, MD Professor School of Human Ecology Department of Psychiatry School of Medicine and Public Health University of Wisconsin-Madison Madison, WI
Dr. Raison is a consultant for Otsuka and Pamlab. He serves on the speakers bureaus for Otsuka, Pamlab, and Sunovion. Dr. Raison’s spouse is an employee of Transdermal Therapeutics.
PROGRAM FACULTY Catherine R. Judd, MS, PA-C Clinical Assistant Professor Southwestern School of Health Professions Department of Physician Assistant Studies Parkland Health & Hospital System Behavioral and Mental Health Services Dallas, TX
Ms. Judd has no relevant financial relationships to disclose.
Cindy Parsons, DNP, ARNP-BC, FAANP Associate Professor of Nursing University of Tampa Tampa, FL
Ms. Parsons has no relevant financial relationships to disclose.
INDEPENDENT REVIEWER Sattaria S. Dilks, DNP, APRN, PMHNP-BC, FAANP Professor and Co-Coordinator Graduate Program College of Nursing McNeese State University Lake Charles, LA
Ms. Dilks has no relevant financial relationships to disclose.
Accredited Provider Disclosure
Anne Norman, DNP, APRN, FNP-BC, and Michele McKay, MSN, APRN, FNP-C, of AANP, have nothing to disclose with regard to commercial support.
Publishing Staff Disclosures
Susan Basilico, Sylvia Nashed, PharmD, and Java Solis, of Haymarket Medical Education, have nothing to disclose with regard to commercial support.
CE for Nurse Practitioners
This program was planned in accordance with AANP’s CE Standards and Policies.
This program is approved for 1.00 contact hours of continuing education (which includes 0.30 RX credit hour(s) pharmacology) by the American Association of Nurse Practitioners.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck, American Association of Nurse Practitioners, and Haymarket Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck, American Association of Nurse Practitioners, and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
If you have any questions relating to the accreditation of this activity, please contact,
American Association of Nurse Practitioners (AANP) Stormy Causey 512-442-4262, ext 5244
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.